Table 2 CML therapies in the course of the disease
Received treatment options | |
- TKI therapies - Other therapies (no TKI) - Allogeneic transplantation | n = 248 (95%) n = 155 (60%) n = 12 (5%) |
Number of TKI lines per patient (N = 248) | |
- Mean - Median (range) | Ø = 1.44 lines 1 line (1–5) |
Distribution of TKI therapies (basis 358 TKI lines) | |
- Imatinib - Nilotinib - Dasatinib - Ponatinib - Bosutinib | n = 202 (56%) n = 79 (22%) n = 70 (20%) n = 4 (1%) n = 3 (1%) |
1st line TKI therapy (N = 248) | |
- Imatinib - Nilotinib - Dasatinib | n = 197 (79%) n = 35 (14%) n = 16 (6%) |
2nd line TKI therapy (N = 71) | |
- Imatinib - Nilotinib - Dasatinib - Bosutinib | n = 4 (6%) n = 23 (32%) n = 42 (59%) n = 2 (3%) |
3rd line TKI therapy (N = 34) | |
- Imatinib - Nilotinib - Dasatinib - Ponatinib | n = 1 (3%) n = 19 (56%) n = 12 (35%) n = 2 (6%) |
Treatment within study protocol | |
- Treatment within clinical trial - No treatment within clinical trial | n = 62 (24%) n = 198 (76%) |